Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 901–930 of 930
Wang, S. J., Haynes, C., Graham, L., Kunuthuru, A., Tuzzolo, G., Surve, A., Isbell, M., He, J., Martin, R., & Bear, H. D. (2026) · Cancers · doi:10.3390/cancers18152480
“Indeed, Liu et al. showed that neoadjuvant treatment with ICB prior to the resection of primary murine breast cancers was superior to the same treatment administered after tumor resection [34].”
Demir, Z. E. F., Kim, A., Ak, B. G., Lee, M. S., Sherlock, T., Maslova, S., Thede, A. T., Talebibarmi, P., DeWitt, M. R., Rutkowski, M. R., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-015671
“67 68 The degree to which FUS-mediated injury productively interfaces with CD40 agonism appears context-dependent and regimen-dependent.”
Li, D., Wang, X., Lu, S., Li, L., Su, Y., Wang, X., Li, Y., Lang, J., & Zhou, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1869222
Zhang, Z., Zhao, R., Hu, Y., Xie, Q., Yu, Y., Li, K., Ding, Z., & Wang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1851289
Gan, X., Yu, Z., Zhang, L., Xie, W., Sun, X., Yue, L., Fang, J., Li, Y., Liu, Y., Liu, Z., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109578
Tartarone, A., Conca, R., Perrone, A., & Lerose, R. (2026) · Immunotherapy · doi:10.1080/1750743x.2026.2721165
Yao, N., Xu, G., Duan, N., Han, F., Li, W., & Qu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908199
“Preclinical and translational data suggest that checkpoint blockade before resection can expand tumor-reactive T-cell clones and generate systemic immune memory (29).”
Micrometastasis as a distinct immunobiological state and therapeutic target
Avalle, S., & Celià-Terrassa, T. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.07.010
Maeseneer, D. J. D., Decruyenaere, A., der Meulen, J. V., Loontiens, S., Rosseel, T., Volders, P., Verbeke, S., Fonteyne, V., Praet, C. V., Berquin, C., et al. (2026) · Cancers · doi:10.3390/cancers18172839
“…platinum with checkpoint inhibition is mechanistically attractive, since platinum induces immunogenic cell death, releases tumour antigens and can convert “cold” tumours into inflamed ones [29–31], and this rationale has produced consistent perioperative benefit across several tumour types [32–37].”
Perioperative strategies for the treatment of HCC
D’Alessio, A., Krendl, F. J., Parente, A., Marino, R., Veloz, M. G., & Tabrizian, P. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102021
Leng, Y., Dan, J., Heng, Q., & Li, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1883161
Sex, Timing, and Outcomes of Curative-Intent Immunotherapy: A Systematic Review and Meta-Analysis
Hollinger, A.-M., Gerard, C. L., Andreas, V. J., Roa‐Díaz, Z. M., Gillessen, S., Michielin, O. A., Pless, M., Peters, S., Micheloud, C., Hayoz, S., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.32635
Ruan, Y., Cao, W., Long, C., Li, C. J., & Han, J. (2026) · BMC Cancer · doi:10.1186/s12885-026-16944-w
“Preclinical and translational evidence from other tumor models also supports greater systemic immune activation with presurgical checkpoint blockade [42, 43].”
Udden, S. N., Obaid, M., Pop, L. M., & Hannan, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198854
“The intact primary tumor can supply antigen and preserve local antigen-presenting and lymphocyte interactions, but can also sustain suppressive myeloid and stromal programs [46,48,50,66].”
InfluentialChen, G., Hu, M., Li, Z., Yang, K., Chen, B., & Xu, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837053
“It may therefore reduce opportunities for continued antigen sampling and de novo T-cell priming (16, 17).”
Multiple Options, One Objective: Clearer Decisions in Resectable Non-Small Cell Lung Cancer
Nohra, E., Najdi, T. A., Karak, A. S. E., Dagher, G., & Karak, F. E. (2026) · Cancers · doi:10.3390/cancers18182963
Zheng, S., Huang, S., Zhang, J., 杨小猛, Ye, P., Wang, W., Li, W., Liu, H., Zhang, C., 廖国庆, et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1933861
Zhang, Y., Paing, H., & Wang, J. (2026) · Cancers · doi:10.3390/cancers18193099
“2 tumors, and dual ICI therapy further improved long-term outcomes, increasing 150-day tumor-free survival to 12%, compared with 6.7% for anti-PD-1 monotherapy [52,53].”
InfluentialLiutti, V. T., Wildiers, H. P. M. W., Sonke, G. S., & Neven, P. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.117064
Real-World Application of PD-1 Inhibitors in High-Grade Glioma: A Case Series
Ren, Y., Guo, X., Xing, H., Kang, X., Liang, T., Shi, Y., Yao, B., Ma, W., & Wang, Y. (2026) · Cancers · doi:10.3390/cancers18193122
“This process, in turn, leads to the upregulation of interferon-γ -related genes and the downregulation of cell cycle and cancer proliferation-related genes within the tumor microenvironment, ultimately enhancing both local and systemic antitumor immune responses [17,25,50,51].”
Lefas, A. Y., Lote, H., & Chau, I. (2026) · Precision Oncology · doi:10.3390/precisoncol1040013
Xin, X., & Miao, R. (2026) · Cancers · doi:10.3390/cancers18193126
“In matched mouse models, checkpoint-based therapy initiated before surgery generated stronger systemic tumor-specific immunity and better control of disseminated disease than the same treatment initiated after surgery [27].”
Perioperative immunotherapy in head and neck squamous cell carcinoma
Hörner, M., Hartmann, S., Adkins, D. R., & Uppaluri, R. (2026) · Cancer · doi:10.1002/cncr.70642
“30 In HNSCC models specifically, neoadjuvant anti–PD - 1 therapy induced enhanced systemic T - cell responses compared to adjuvant therapy alone.”
Hörner, M., Hartmann, S., & Müller-Richter, U. (2026) · Die MKG-Chirurgie · doi:10.1007/s12285-026-00594-9
Liu, D., Yang, L., Hu, M., Du, H., Chen, Y., 朱瑶瑶, Kang, J., Yuan, X., Yang, S., Xu, Q., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02984-y
“16 Cytoreduction before CRT may also improve treatment compliance and facilitate safer delivery of thoracic radiotherapy.”
Rawson, R. V., Burton, E. M., & Tetzlaff, M. T. (2026) · Histopathology · doi:10.1111/his.70281
Freeman, H., Rawson, C. D., Al-Saidi, N., Lucke-Wold, B. P., Karsy, M. J., & Pahlevani, M. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002406
Truong, A., Chen, L., Lee, R. H., Wu, X. C., Kang, H., El‐Sayed, I. H., George, J. R., Heaton, C. M., Likhterov, I., Chow, M. S., et al. (2026) · Head & Neck · doi:10.1002/hed.70505
Komatsu, T., Patel, R. D., & Tiersten, A. (2026) · Cancers · doi:10.3390/cancers18213490
Jin, N., Zhang, X., Li, Z., Zhou, Y., Wang, Z., & Wang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.2007560
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.